The two models include the following endpoints: Mini-Mental State Examination (MMSE), Alzheimer’s Disease Assessment Scale—cognitive sub-scale with 13 items (ADAS-Cog13), Clinical Dementia Rating—sum of boxes (CDR-SB), volumes of the left and right hippocampus and lateral ventricles, Aβ1–42 and p-tau181 levels in the cerebrospinal fluid (CSF), standard uptake value ratio (SUVR) for Amyloid PET and Tau PET scans. The gene discussed is MAPT; the disease is Alzheimer disease.